Spots Global Cancer Trial Database for Combination of Rituximab and NK Immunotherapy for B Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Combination of Rituximab and NK Immunotherapy for B Lymphoma
Official Title:
Study ID: NCT02843061
Conditions
Study Description
Brief Summary: The aim of this study is the safety and efficacy of Rituximab plus NK immunotherapy to recurrent B lymphoma.
Detailed Description: By enrolling patients with B lymphoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using Rituximab and natural killer (NK) cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Eligibility
Minimum Age: 30 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Institute in Fuda cancer hospital, Guangzhou, Guangdong, China
Contact Details
Name: Jibing Chen, MD, PhD
Affiliation: Fuda Cancer Hospital, Guangzhou
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
